A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (RedirecTT-1)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04586426 |
|
Recruitment Status :
Recruiting
First Posted : October 14, 2020
Last Update Posted : April 24, 2024
|
Sponsor:
Janssen Research & Development, LLC
Information provided by (Responsible Party):
Janssen Research & Development, LLC
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R[s]) and schedule for the study treatment (Part 1), to characterize the safety of the RP2R(s) for the study treatment (Part 2) and to evaluate the anticancer activity of talquetamab + teclistamab in participants with relapsed or refractory multiple myeloma and extramedullary disease (EMD) (Part 3).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Multiple Myeloma | Drug: Talquetamab Drug: Teclistamab Drug: Daratumumab | Phase 1 Phase 2 |
Multiple myeloma is a malignant plasma cell disorder characterized by production of monoclonal proteins (M proteins), which are comprised of pathologic immunoglobulins (Ig) or fragments of such, which have subsequently lost their normal function. Rationale for combining talquetamab and teclistamab is the targeting of multiple proteins on the surface of multiple myeloma cells resulting in cell lysis. This study consists of 3 periods: screening phase (up to 28 days), treatment phase (start of study drug administration and continues until the completion of the end of treatment [EOT] visit); and a post-treatment follow-up phase (after end of treatment and up to 16 weeks after last dose of study drug(s) for each participant). End of study is defined as 2 years after the last participant has received his or her initial dose of the treatment combination. Total duration of study is Approximately 5 years. Efficacy, safety, pharmacokinetics (PK), immunogenicity, and biomarkers will be assessed at specified time points during this study. Participants safety and study conduct will be monitored throughout the study.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 208 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Sequential Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 1b/2 Dose Escalation and Expansion Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma |
| Actual Study Start Date : | December 15, 2020 |
| Estimated Primary Completion Date : | June 27, 2025 |
| Estimated Study Completion Date : | August 29, 2025 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Multiple myeloma
MedlinePlus related topics:
Multiple Myeloma
Drug Information
available for:
Daratumumab
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Part 1: Dose Escalation
Participants will receive tec+tal with or without daratumumab in 28-day cycles following initial step-up doses.
|
Drug: Talquetamab
Talquetamab will be administered by subcutaneous (SC) injection.
Other Name: JNJ-64407564 Drug: Teclistamab Teclistamab will be administered by SC injection.
Other Name: JNJ-64007957 Drug: Daratumumab Daratumumab will be administered by SC injection. |
|
Experimental: Part 2: Dose Expansion
Participants will receive treatment doses (combination of tal+tec and dara+tal+tec regimens) which will be determined by the recommended Phase 2 regimen (s) (RP2R[s]) of the study treatment identified in Part 1.
|
Drug: Talquetamab
Talquetamab will be administered by subcutaneous (SC) injection.
Other Name: JNJ-64407564 Drug: Teclistamab Teclistamab will be administered by SC injection.
Other Name: JNJ-64007957 Drug: Daratumumab Daratumumab will be administered by SC injection. |
|
Experimental: Part 3: Phase 2
Participants will receive teclistamab + talquetamab combination therapy, at the RP2R selected from Part 1 and Part 2.
|
Drug: Talquetamab
Talquetamab will be administered by subcutaneous (SC) injection.
Other Name: JNJ-64407564 Drug: Teclistamab Teclistamab will be administered by SC injection.
Other Name: JNJ-64007957 |
Primary Outcome Measures :
- Part 1: Number of Participants with Dose Limiting Toxicity (DLT) [ Time Frame: Approximately 5 years ]The dose limiting toxicities are based on drug related adverse events and defined as any of the following events: hematological or non-hematological toxicity of grade 3 or higher.
- Part 1: Severity of DLT as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) [ Time Frame: Approximately 5 years ]Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening, and Grade 5= Death related to adverse event.
- Part 2: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability [ Time Frame: Approximately 5 years ]An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect, and suspects transmission of any infectious agent via a medicinal product, is medically important.
- Part 2: Number of Participants with Adverse Events and SAEs by Severity [ Time Frame: Approximately 5 years ]Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening, and Grade 5= Death related to adverse event.
- Part 3: Overall Response Rate (ORR) [ Time Frame: Approximately 5 years ]ORR is defined as the percentage of participants who have a partial response (PR) or better according Independent Review Committees (IRC).
Secondary Outcome Measures :
- Parts 1, 2 and 3: Serum Concentration of Talquetamab [ Time Frame: Approximately 5 years ]Serum samples will be analyzed to determine concentrations of talquetamab using a validated, specific, and sensitive immunoassay method.
- Parts 1, 2 and 3: Serum Concentration of Teclistamab [ Time Frame: Approximately 5 years ]Serum samples will be analyzed to determine concentrations of teclistamab using a validated, specific, and sensitive immunoassay method.
- Part 1 and Part 2: Serum Concentration of Daratumumab [ Time Frame: Approximately 5 years ]Serum samples will be analyzed to determine concentrations of daratumumab using a validated, specific, and sensitive immunoassay method.
- Parts 1, 2 and 3: Number of Participants with Anti-Drug Antibodies to Talquetamab [ Time Frame: Approximately 5 years ]Number of participants with anti-drug antibodies to talquetamab will be assessed.
- Parts 1, 2 and 3: Number of Participants with Anti-Drug Antibodies to Teclistamab [ Time Frame: Approximately 5 years ]Number of participants with anti-drug antibodies to teclistamab will be assessed.
- Part 1 and Part 2: Number of Participants with Anti-Drug Antibodies to Daratumumab [ Time Frame: Approximately 5 years ]Number of participants with anti-drug antibodies to daratumumab will be assessed.
- Part 1 and Part 2: Overall Response Rate (ORR) [ Time Frame: Approximately 5 years ]ORR is defined as the percentage of participants who have a partial response (PR) or better according to the International Myeloma Working Group (IMWG) criteria.
- Parts 1, 2 and 3: Very Good Partial Response (VGPR) or Better Response Rate [ Time Frame: Approximately 5 years ]VGPR or better response rate (sCR+CR+VGPR) is defined as the percentage of participants who achieve a VGPR or better response according to the IMWG criteria.
- Parts 1, 2 and 3: Complete Response (CR) or Better Response Rate [ Time Frame: Approximately 5 years ]CR or better response rate (sCR+CR) is defined as the percentage of participants who achieve a CR or better response according to the IMWG criteria.
- Part 1, 2 and 3: Stringent Complete Response (sCR) Rate [ Time Frame: Approximately 5 years ]sCR rate is defined as the percentage of participants who achieve a sCR according to the IMWG criteria.
- Parts 1, 2 and 3: Duration of Response (DOR) [ Time Frame: Approximately 5 years ]DOR will be calculated among responders (with PR or better) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the IMWG criteria.
- Parts 1, 2 and 3: Time to Response [ Time Frame: Approximately 5 years ]Time to response is defined as the time between date of first dose of study drug and the first efficacy evaluation that the participant has met all criteria for PR or better.
- Part 3: Progression free Survival (PFS) [ Time Frame: Approximately 5 years ]PFS is defined as the time from the date of first dose to the date of first documented disease progression, as defined in the IMWG criteria, or death due to any cause, whichever occurs first.
- Part 3: Overall Survival (OS) [ Time Frame: Approximately 5 years ]OS is measured from the date of first dose to the date of the participant's death.
- Part 3: Number of Participants with Adverse Events [ Time Frame: Approximately 5 years ]An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.
- Part 3: Number of Participants with Adverse Events by Severity [ Time Frame: Approximately 5 years ]Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening, and Grade 5= Death related to adverse event.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Documented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria
- Part 1 and 2: Participant could not tolerate or has disease that is relapsed or refractory to established therapies, including the last line of therapy. Part 3: (a) Relapsed or refractory disease, and exposed to a PI, IMiD, and an anti-CD38 mAb; (b) Documented evidence of progressive disease based on investigator's determination of response by IMWG criteria on or after their last regimen
- Part 1 and Part 2: Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1 at screening and immediately before the start of study drug administration. Part 3: ECOG performance status grade of 0, 1, or 2 at screening and immediately before the start of study drug administration
Exclusion Criteria:
- All Parts: Targeted therapy, epigenetic therapy, or treatment with an investigational treatment or an invasive investigational medical device within 21 days or at least 5 half-lives, whichever is less. Part 3: prior BCMA targeted bispecific antibody therapy; prior GPRC5D targeted therapy
- All Parts: Allogeneic stem cell transplant within 6 months before the first dose of study treatment.
- All Parts: Central nervous system involvement or clinical signs of meningeal involvement of multiple myeloma.
- All Parts: Active plasma cell leukemia (greater than [>]2.0*10^9/L plasma cells by standard differential), Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M- protein, and skin changes), or primary amyloid light chain amyloidosis
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04586426
Contacts
| Contact: Study Contact | 844-434-4210 | Participate-In-This-Study@its.jnj.com |
Locations
Show 40 study locations
Sponsors and Collaborators
Janssen Research & Development, LLC
Investigators
| Study Director: | Janssen Research & Development, LLC Clinical Trial | Janssen Research & Development, LLC |
| Responsible Party: | Janssen Research & Development, LLC |
| ClinicalTrials.gov Identifier: | NCT04586426 |
| Other Study ID Numbers: |
CR108901 2019-004124-38 ( EudraCT Number ) 64007957MMY1003 ( Other Identifier: Janssen Research & Development, LLC ) 2023-503439-16-00 ( Registry Identifier: EUCT number ) |
| First Posted: | October 14, 2020 Key Record Dates |
| Last Update Posted: | April 24, 2024 |
| Last Verified: | April 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu |
| URL: | https://www.janssen.com/clinical-trials/transparency |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | Yes |
Additional relevant MeSH terms:
|
Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias |
Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders Immune System Diseases Daratumumab Antineoplastic Agents |